Search research articles
Contact Us
Filters
Showing results (161-170 of 379) with videos related to
Page
of 38
Sort By:
Haematologica
|
August 5, 2018
Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, et al.
Haematologica
|
January 2, 2019
Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment
Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, et al.
Blood
|
May 10, 2005
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis
Boris Böll, Hinrich Hansen, Friederike Heuck, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
March 22, 2003
Soluble tissue factor induces coagulation on tumor endothelial cells in vivo if coadministered with low-dose lipopolysaccharides
Jana Philipp, Ariane Dienst, Maike Unruh, et al.
Biological Chemistry
|
January 30, 2008
Ribosome display and selection of human anti-cD22 scFvs derived from an acute lymphocytic leukemia patient
Achim Rothe, Anne Nathanielsz, Frank Oberhäuser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2004
Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group
Henning Bredenfeld, Jeremy Franklin, Lucia Nogova, et al.
The Cochrane Database of Systematic Reviews
|
December 14, 2012
Erythropoietin or darbepoetin for patients with cancer
Thomy Tonia, Annette Mettler, Nadège Robert, et al.
The Cochrane Database of Systematic Reviews
|
February 18, 2011
Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Christine Herbst, Fareed Ahmed Rehan, Nicole Skoetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2011
Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group
Beate Klimm, Jeremy Franklin, Harald Stein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2005
Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group
Beate Klimm, Thorsten Reineke, Heinz Haverkamp, et al.
Page
of 38
Search research articles
Search
Showing results (161-170 of 379) with videos related to
Sort By:
Page
of 38
Haematologica
|
August 5, 2018
Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, et al.
Haematologica
|
January 2, 2019
Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment
Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, et al.
Blood
|
May 10, 2005
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis
Boris Böll, Hinrich Hansen, Friederike Heuck, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
March 22, 2003
Soluble tissue factor induces coagulation on tumor endothelial cells in vivo if coadministered with low-dose lipopolysaccharides
Jana Philipp, Ariane Dienst, Maike Unruh, et al.
Biological Chemistry
|
January 30, 2008
Ribosome display and selection of human anti-cD22 scFvs derived from an acute lymphocytic leukemia patient
Achim Rothe, Anne Nathanielsz, Frank Oberhäuser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2004
Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group
Henning Bredenfeld, Jeremy Franklin, Lucia Nogova, et al.
The Cochrane Database of Systematic Reviews
|
December 14, 2012
Erythropoietin or darbepoetin for patients with cancer
Thomy Tonia, Annette Mettler, Nadège Robert, et al.
The Cochrane Database of Systematic Reviews
|
February 18, 2011
Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
Christine Herbst, Fareed Ahmed Rehan, Nicole Skoetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2011
Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group
Beate Klimm, Jeremy Franklin, Harald Stein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2005
Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group
Beate Klimm, Thorsten Reineke, Heinz Haverkamp, et al.
Page
of 38